FDA approves Viatris' low-dose estrogen weekly patch?

5.0 puan (24s)Health & MedicineWeekly2g

PolymarketKullanılabilirliği kontrol etKYC yok%2 ücretDoğrulanmış sonuçlanma verisiOrta düzey kalibre

Güncel ima edilen olasılık

Evet 64.4%-0.1pt

Piyasa kalitesi

32 / 100

Düşük kalite

24s Hacim

₺0

Likidite

₺5,1 B

Düşük likidite

Alis / Satis

41.0% / 88.0%

Spread

47.0 pt

Geniş spread

7g Değişim

+9.5 pts

Piyasa verileri

17 dakika önce guncellendi

1 Tem 26 6:1430 Tem 26 17:59

Trendler

Sonuç24sOlasılık

Yalnızca sanal bakiye, gerçek para yokYatırım tavsiyesi değildir

Seçilen sonuç

Yes65%

Tutar (USDT)

Kurallar

As of market creation, the FDA's expected decision date for the specified application is July 30, 2026.

This market will resolve to "Yes" if the U.S.
Food and Drug Administration (FDA) grants full or conditional approval for Viatris's low-dose estrogen weekly patch for contraception by August 13, 2026, 11:59 PM ET.
Otherwise, this market will resolve to "No."
An approval is defined as: For new drugs: FDA issuance of an approval letter for a New Drug Application (NDA) or Biologics License Application (BLA) For already-marketed drugs seeking new indications: FDA approval of a supplemental NDA (sNDA) or supplemental BLA (sBLA) for the specific indication referenced For generic drugs: FDA approval of an Abbreviated New Drug Application (ANDA) For biosimilars: FDA approval of a 351(k) application
The following constitute qualifying approvals: Standard approval (traditional approval based on clinical benefit), Accelerated approval (based on surrogate endpoints), Approval with Risk Evaluation and Mitigation Strategy (REMS), Approval with restricted distribution or indication limitations, except compassionate use/expanded access programs

Hacim trendi

2 Tem20g veri21 Tem

İlgili Piyasalar

Will AbbVie Q2 Global Skyrizi net revenues be above __?

₺0

$19B: 4%

POLYMARKET

Chipotle chicken burrito price in July 2026

₺947,9 B

At least $9.75: 99%

KALSHI

What price will Bitcoin hit July 27-August 2?

₺317,8 B

↓ 62,000: 66%

POLYMARKET

Price of NVIDIA B200 compute by Jul 31, 2026?

₺238,2 B

Above $3.96: 99%

KALSHI

Price of NVIDIA H100 SXM compute by Jul 31, 2026?

₺197 B

Above $2.71: 48%

KALSHI

What price will Ethereum hit July 27-August 2?

₺120,9 B

↓ 1,900: 100%

POLYMARKET

Bu konularda aktif

EthereumETH$1,876.48-3.54%

BitcoinBTC$63,210.53-3.00%

SolanaSOL$73.28-4.05%

XRPXRP$1.06-4.35%

BNBBNB$565.32-1.37%

DogecoinDOGE$0.0697-4.19%

İlgili Haberler

NVIDIA BioNeMo Toolkit Accelerates AI-Driven Drug DiscoveryBlockchain.News

OpenAI Launches GeneBench-Pro to Test AI in BiologyBlockchain.News

Google Transfers Open Health Stack to Linux FoundationBlockchain.News

Kurallar

As of market creation, the FDA's expected decision date for the specified application is July 30, 2026.

This market will resolve to "Yes" if the U.S.
Food and Drug Administration (FDA) grants full or conditional approval for Viatris's low-dose estrogen weekly patch for contraception by August 13, 2026, 11:59 PM ET.
Otherwise, this market will resolve to "No."
An approval is defined as: For new drugs: FDA issuance of an approval letter for a New Drug Application (NDA) or Biologics License Application (BLA) For already-marketed drugs seeking new indications: FDA approval of a supplemental NDA (sNDA) or supplemental BLA (sBLA) for the specific indication referenced For generic drugs: FDA approval of an Abbreviated New Drug Application (ANDA) For biosimilars: FDA approval of a 351(k) application
The following constitute qualifying approvals: Standard approval (traditional approval based on clinical benefit), Accelerated approval (based on surrogate endpoints), Approval with Risk Evaluation and Mitigation Strategy (REMS), Approval with restricted distribution or indication limitations, except compassionate use/expanded access programs

FDA approves Viatris' low-dose estrogen weekly patch?

5.0 puan (24s)Health & MedicineWeekly2g

PolymarketKullanılabilirliği kontrol etKYC yok%2 ücretDoğrulanmış sonuçlanma verisiOrta düzey kalibre

Güncel ima edilen olasılık

Evet 64.4%-0.1pt

Piyasa kalitesi

32 / 100

Düşük kalite

24s Hacim

₺0

Likidite

₺5,1 B

Düşük likidite

Alis / Satis

41.0% / 88.0%

Spread

47.0 pt

Geniş spread

7g Değişim

+9.5 pts

Piyasa verileri

17 dakika önce guncellendi

1 Tem 26 6:1430 Tem 26 17:59

Trendler

Sonuç24sOlasılık

Yalnızca sanal bakiye, gerçek para yokYatırım tavsiyesi değildir

Seçilen sonuç

Yes65%

Tutar (USDT)

Kurallar

As of market creation, the FDA's expected decision date for the specified application is July 30, 2026.

This market will resolve to "Yes" if the U.S.
Food and Drug Administration (FDA) grants full or conditional approval for Viatris's low-dose estrogen weekly patch for contraception by August 13, 2026, 11:59 PM ET.
Otherwise, this market will resolve to "No."
An approval is defined as: For new drugs: FDA issuance of an approval letter for a New Drug Application (NDA) or Biologics License Application (BLA) For already-marketed drugs seeking new indications: FDA approval of a supplemental NDA (sNDA) or supplemental BLA (sBLA) for the specific indication referenced For generic drugs: FDA approval of an Abbreviated New Drug Application (ANDA) For biosimilars: FDA approval of a 351(k) application
The following constitute qualifying approvals: Standard approval (traditional approval based on clinical benefit), Accelerated approval (based on surrogate endpoints), Approval with Risk Evaluation and Mitigation Strategy (REMS), Approval with restricted distribution or indication limitations, except compassionate use/expanded access programs

Hacim trendi

2 Tem20g veri21 Tem

İlgili Piyasalar

Will AbbVie Q2 Global Skyrizi net revenues be above __?

₺0

$19B: 4%

POLYMARKET

Chipotle chicken burrito price in July 2026

₺947,9 B

At least $9.75: 99%

KALSHI

What price will Bitcoin hit July 27-August 2?

₺317,8 B

↓ 62,000: 66%

POLYMARKET

Price of NVIDIA B200 compute by Jul 31, 2026?

₺238,2 B

Above $3.96: 99%

KALSHI

Price of NVIDIA H100 SXM compute by Jul 31, 2026?

₺197 B

Above $2.71: 48%

KALSHI

What price will Ethereum hit July 27-August 2?

₺120,9 B

↓ 1,900: 100%

POLYMARKET

Bu konularda aktif

EthereumETH$1,876.48-3.54%

BitcoinBTC$63,210.53-3.00%

SolanaSOL$73.28-4.05%

XRPXRP$1.06-4.35%

BNBBNB$565.32-1.37%

DogecoinDOGE$0.0697-4.19%

İlgili Haberler

NVIDIA BioNeMo Toolkit Accelerates AI-Driven Drug DiscoveryBlockchain.News

OpenAI Launches GeneBench-Pro to Test AI in BiologyBlockchain.News

Google Transfers Open Health Stack to Linux FoundationBlockchain.News

Kurallar

As of market creation, the FDA's expected decision date for the specified application is July 30, 2026.

This market will resolve to "Yes" if the U.S.
Food and Drug Administration (FDA) grants full or conditional approval for Viatris's low-dose estrogen weekly patch for contraception by August 13, 2026, 11:59 PM ET.
Otherwise, this market will resolve to "No."
An approval is defined as: For new drugs: FDA issuance of an approval letter for a New Drug Application (NDA) or Biologics License Application (BLA) For already-marketed drugs seeking new indications: FDA approval of a supplemental NDA (sNDA) or supplemental BLA (sBLA) for the specific indication referenced For generic drugs: FDA approval of an Abbreviated New Drug Application (ANDA) For biosimilars: FDA approval of a 351(k) application
The following constitute qualifying approvals: Standard approval (traditional approval based on clinical benefit), Accelerated approval (based on surrogate endpoints), Approval with Risk Evaluation and Mitigation Strategy (REMS), Approval with restricted distribution or indication limitations, except compassionate use/expanded access programs